Home/Pipeline/NanoDDI

NanoDDI

HIV

Pre-clinicalActive

Key Facts

Indication

HIV

Phase

Pre-clinical

Status

Active

Company

Continuity Biosciences

About Continuity Biosciences

Continuity Biosciences is an early-stage biotech innovator building a portfolio of precision drug delivery platforms designed to enhance the efficacy and safety of existing and emerging therapies. The company's core strategy involves creating implantable and localized systems—such as the NICHE platform for cell therapy and iontophoretic devices for targeted chemotherapy—that protect therapeutics and maximize impact at the disease site while minimizing systemic exposure. With a focus on significant unmet needs in Type 1 diabetes, pancreatic cancer, HIV, and other conditions, Continuity is positioning itself at the intersection of advanced engineering and deep biological insight. The company has secured strategic investment from Breakthrough T1D to advance its lead program toward human trials.

View full company profile

Therapeutic Areas

Type 1 Diabetes Oncology HIV Medical Aesthetics

Other HIV Drugs

Drug	Company	Phase	Status
Vaxine HIV Vaccine	Vaxine	Preclinical	Active
OraQuick® HIV Self-Test	OraSure	Commercial	FDA Approved; Marketed
Tenofovir Disoproxil Fumarate	Hetero	Commercial	Active
HIV Gene Therapy	Nanite	Pre-clinical	Active
RGFields for HIV	Anapole Technologies	Clinical (phase unspecified)	Active
HIV mAb Program	Adnexus	Pre-clinical	Active
Undisclosed Program	EnnoDC	Phase 1	Active
O2-16 Series	OyaGen	Preclinical	Active
SBX 2048	Stramsen Biotech	Early-stage Clinical	Active
ALF Platform	Senzo	Pre-clinical	Active
Gilead HIV Franchise	Royalty Pharma	Marketed	Active
ANKTIVA-based regimens	ImmunityBio	Phase 1/2	Active